File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: T lymphocyte activation in euthyroid Graves' ophthalmopathy: Soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production

TitleT lymphocyte activation in euthyroid Graves' ophthalmopathy: Soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production
Authors
Issue Date1989
Citation
Acta Endocrinologica, 1989, v. 120 n. 5, p. 602-609 How to Cite?
AbstractThe present study was undertaken to examine the cellular control arm of the immune response with regard to T lymphocyte proliferation in euthyroid Graves' ophthalmopathy. Twenty patients with euthyroid Graves' ophthalmopathy (7 on antithyroid drugs and 13 on no treatment) and 18 healthy controls were studied in an infection-free period. Mitogen-stimulated cellular interleukin 2 (IL2) receptor expression, soluble interleukin 2 receptor release, and interleukin 2 production, were studied in peripheral blood mononuclear cells cultured for 24 h. The cellular IL2 receptor expression and soluble IL2 receptor release did not differ between the patients and healthy controls. In contrast, IL2 production in response to pokeweed mitogen stimulation was increased in lymphocytes from patients with Graves' ophthalmopathy. The IL2 release did not correlate with the quantities of cellular and soluble IL2 receptor. The mitogen-stimulated cellular IL2 receptor expression, IL2 receptor rleease, and IL2 production did not differ between patients with or without carbimazole therapy. Despite a suggested role of autoreactive T cells in mediating the development and propagation of autoimmune thyroid disease, this study fails to demonstrate a defective T lymphocyte activation state in patients with Graves' ophthalmopathy during an euthyroid state.
Persistent Identifierhttp://hdl.handle.net/10722/161797
ISSN
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, KNen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorChow, CCen_HK
dc.contributor.authorCockram, CSen_HK
dc.date.accessioned2012-09-05T05:15:06Z-
dc.date.available2012-09-05T05:15:06Z-
dc.date.issued1989en_HK
dc.identifier.citationActa Endocrinologica, 1989, v. 120 n. 5, p. 602-609en_HK
dc.identifier.issn0001-5598en_HK
dc.identifier.urihttp://hdl.handle.net/10722/161797-
dc.description.abstractThe present study was undertaken to examine the cellular control arm of the immune response with regard to T lymphocyte proliferation in euthyroid Graves' ophthalmopathy. Twenty patients with euthyroid Graves' ophthalmopathy (7 on antithyroid drugs and 13 on no treatment) and 18 healthy controls were studied in an infection-free period. Mitogen-stimulated cellular interleukin 2 (IL2) receptor expression, soluble interleukin 2 receptor release, and interleukin 2 production, were studied in peripheral blood mononuclear cells cultured for 24 h. The cellular IL2 receptor expression and soluble IL2 receptor release did not differ between the patients and healthy controls. In contrast, IL2 production in response to pokeweed mitogen stimulation was increased in lymphocytes from patients with Graves' ophthalmopathy. The IL2 release did not correlate with the quantities of cellular and soluble IL2 receptor. The mitogen-stimulated cellular IL2 receptor expression, IL2 receptor rleease, and IL2 production did not differ between patients with or without carbimazole therapy. Despite a suggested role of autoreactive T cells in mediating the development and propagation of autoimmune thyroid disease, this study fails to demonstrate a defective T lymphocyte activation state in patients with Graves' ophthalmopathy during an euthyroid state.en_HK
dc.languageengen_US
dc.relation.ispartofActa Endocrinologicaen_HK
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshCarbimazole - Administration & Dosageen_US
dc.subject.meshCells, Cultureden_US
dc.subject.meshFemaleen_US
dc.subject.meshGraves Disease - Drug Therapy - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInterleukin-2 - Biosynthesisen_US
dc.subject.meshLymphocyte Activation - Drug Effectsen_US
dc.subject.meshMaleen_US
dc.subject.meshMitogens - Pharmacologyen_US
dc.subject.meshRadioimmunoassayen_US
dc.subject.meshReceptors, Interleukin-2 - Biosynthesis - Drug Effectsen_US
dc.subject.meshT-Lymphocytes - Immunologyen_US
dc.titleT lymphocyte activation in euthyroid Graves' ophthalmopathy: Soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 productionen_HK
dc.typeArticleen_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2786308-
dc.identifier.scopuseid_2-s2.0-0024547142en_HK
dc.identifier.volume120en_HK
dc.identifier.issue5en_HK
dc.identifier.spage602en_HK
dc.identifier.epage609en_HK
dc.identifier.isiWOS:A1989U682100010-
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridChow, CC=8252323700en_HK
dc.identifier.scopusauthoridCockram, CS=7006379262en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats